aap

110% LOQTEQ® sales growth in Q3, total sales increase by 20% to EUR 7.6 million

aap Implantate AG / aap: 110% LOQTEQ® sales growth in Q3, total sales increase by 20% to EUR 7.6 million . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) generated, according to preliminary figures, sales of EUR 7.6 million in the third quarter of 2014, thereby achieving a result at the upper range of the forecast made at the beginning of the quarter of EUR 7.0 million to EUR 8.0 million. aap generated total sales of EUR 22.8 million in the first nine months of 2014, of which EUR 21.8 million is attributable to the continued operations (aap Implantate AG excluding EMCM B.V.). As a result of the sale of EMCM B.V. on February 28, the sales figures for the first half-year include sales from EMCM for January and February totaling EUR 1.0 million.

In a year-on-year comparison, the continued operations quarterly sales grew by 20% to EUR 7.6 million over the corresponding sales of EUR 6.3 million in the third quarter of 2013. The key factors in this development were strong quarterly business in the trauma area, mainly with the LOQTEQ® product portfolio as well as continued growth in our biomaterials business (biomaterials, bone cements and cementing technology). These trends were also decisive for the 15% increase in nine-month sales to EUR 21.8 million from continued operations. The dynamism of the course of business with product sales can been seen clearly here, as the previous year's sales figures for the first three quarters included EUR 2.4 million in revenue from project business, which only came to EUR 0.3 million in the first nine months of 2014.

In EUR million	Q3/2014	Q3/2013	Change
Sales from continued operations	7.6	6.3	20%

In EUR million	9m/2014	9m/2013	Change
Sales from continued operations	21.8	19.0	15%
Sales from discontinued operations	1.0*	9.4*²	-90%
Sales total	22.8	28.4	-20%

*  Sales revenues EMCM B.V. 01-02/2014: EUR 1.2 million less consolidation effects (EUR 0.2 million)
*² Sales revenues EMCM B.V. 01-09/2013: EUR 10.1 million less consolidation effects (EUR 0.7 million)

Sales in the trauma area amounted to EUR 3.3 million in the third quarter, of which EUR 2.4 million was attributable to sales of products from the LOQTEQ® portfolio. With a significant increase of LOQTEQ® sales of 110% on the same quarter in the previous year, the pace of growth was further accelerated. The trauma area saw growth of 29% to EUR 8.4 million in the nine-month period, and here the LOQTEQ® system was also a key factor, with growth of 68% to EUR 5.3 million.